This morning, Array Biopharma will outline its plans to investors to get its first wholly-owned drug, a treatment for the blood cancer multiple myeloma, approved by the Food and Drug Administration. Codenamed ARRY-520, the medicine is a exciting because it is a new class of medicine, completely different from the immunomodulatory agents, including thalidomide, Revlimid, and Pomalyst, all made by Celgene CELG -1.83%, and the proteasome inhibitors Velcade, sold by Takeda, and Kyprolis, from Amgen AMGN -0.32%. “In patients that have failed everything we believe 520 can offer benefit,” says Ron Squarer, Array’s chief executive.
Hey, check out all the research scientist jobs. Post your resume today!
